Summary:
This is a 16-week, multicenter, randomized, parallel-group, double-blind, controlled study. Subjects , who will be randomized in a 3:3:2 ratio to DFD-29 (40 mg), Doxycycline capsules 40 mg, or Placebo once daily for 16 weeks.
Subject visits are scheduled at Screening, Baseline (Day 1), and Weeks 2, 4, 8, 12, and 16.
Qualified Participants Must:
• Males and Females
•
At least 18 years old
•
Diagnosed with moderate to severe papulopustular rosacea
Qualified Participants May Receive:
· Study Medication and Study related office visits, at no cost.
· Qualified Participants will receive up to $420 for time and travel
· NO Health Insurance necessary.